ATR-04
Phase 1/2Withdrawn 0 watching 0 views this weekπ€ Quiet
33
Development Stage
β
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Epidermal Growth Factor
Conditions
Epidermal Growth Factor, Papulopustular Rosacea
Trial Timeline
Jan 1, 2024 β Jan 1, 2026
NCT ID
NCT04731259About ATR-04
ATR-04 is a phase 1/2 stage product being developed by Azitra for Epidermal Growth Factor. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04731259. Target conditions include Epidermal Growth Factor, Papulopustular Rosacea.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04731259 | Phase 1/2 | Withdrawn |
Competing Products
13 competing products in Epidermal Growth Factor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HER3-DXd | Daiichi Sankyo | Pre-clinical | 23 |
| Erlotinib | Astellas Pharma | Phase 2 | 52 |
| radio-labeled naquotinib + naquotinib | Astellas Pharma | Phase 1 | 33 |
| KRN23 | Kyowa Kirin | Phase 2 | 52 |
| SHR6390 + placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| ABT-414 | AbbVie | Pre-clinical | 23 |
| Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Merck | Phase 3 | 77 |
| Venetoclax + Fulvestrant | Roche | Phase 2 | 52 |
| Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine | Roche | Phase 3 | 77 |
| Palbociclib + Everolimus + Exemestane | Pfizer | Phase 1/2 | 40 |
| Palifermin | Swedish Orphan Biovitrum | Phase 1/2 | 40 |
| Crysvita (burosumab-twza) Treatment | Ultragenyx Pharmaceutical | Approved | 80 |
| FDX104 (4% Doxycycline) | Vyne Therapeutics | Phase 2 | 44 |